Home » Topics » Disease categories and therapies » Immune

Immune
RSS

North American Vaccine submits NeisVac-C for U.K. approval

Jan. 25, 2000

Peptide Therapeutics' C. difficile vaccine: positive phase I/II results

Jan. 25, 2000

Pfizer presents new series of JAK3 inhibitors for autoimmune diseases

Jan. 24, 2000

SmithKline Beecham signs CpG DNA immune stimulant agreement

Jan. 21, 2000

North American Vaccine to seek NeisVac-C approval in U.K. shortly

Jan. 20, 2000

QS-21 license granted to Elan

Jan. 20, 2000

Avant's cholera vaccine to enter phase IIb trial

Jan. 19, 2000

Isolation of unnamed tick-borne bacterium causing HGE patented by Aquila

Jan. 17, 2000

FDA accepts NDA for new Rapamune formulation

Jan. 14, 2000

KF-20444 has potent immunosuppressive activity

Jan. 14, 2000

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 15, 2026.
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Microbiota modulates the antidepressant effects of GLP-1 analogues
BioWorld Science
Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...
Enliven’s phase I CML data Enable phase III with BCR/ABL1 bid
BioWorld
Tolerability is a key factor in the appeal of Enliven Therapeutics Inc.’s ELVN-001 for previously treated chronic myeloid leukemia (CML), which yielded positive...